{"organizations": [], "uuid": "135c0ba8c12c30e3399d936e8f9b82c025fc3250", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mereo-biopharma-group-withdraws-pr/brief-mereo-biopharma-group-withdraws-proposed-nasdaq-listing-idUSFWN1S304Q", "country": "US", "domain_rank": 408, "title": "Mereo Biopharma Group withdraws proposed Nasdaq listing", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T14:10:00.000+03:00", "replies_count": 0, "uuid": "135c0ba8c12c30e3399d936e8f9b82c025fc3250"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mereo-biopharma-group-withdraws-pr/brief-mereo-biopharma-group-withdraws-proposed-nasdaq-listing-idUSFWN1S304Q", "ord_in_thread": 0, "title": "Mereo Biopharma Group withdraws proposed Nasdaq listing", "locations": [], "entities": {"persons": [{"name": "denise scots-knight", "sentiment": "none"}, {"name": "emma rumney", "sentiment": "none"}], "locations": [], "organizations": [{"name": "mereo biopharma group plc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "nasdaq", "sentiment": "negative"}, {"name": "mereo biopharma group", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - Mereo Biopharma Group PLC:\n* COMPANY HAS WITHDRAWN GLOBAL OFFERING AND POSTPONED ITS PROPOSED LISTING OF ITS AMERICAN DEPOSITARY SHARES (“ADSS”) ON NASDAQ GLOBAL MARKET THAT WAS PREVIOUSLY ANNOUNCED ON APRIL 9, 2018\n* COMPANY BELIEVES THAT CURRENT MARKET CONDITIONS ARE NOT CONDUCIVE FOR AN OFFERING ON TERMS THAT WOULD BE IN BEST INTERESTS OF ITS SHAREHOLDERS.\n* DENISE SCOTS-KNIGHT, CHIEF EXECUTIVE OFFICER OF MEREO BIOPHARMA GROUP PLC COMMENTED: “WE RECEIVED POSITIVE FEEDBACK AND STRONG LEVELS OF INSTITUTIONAL INTEREST DURING OFFERING PROCESS Source text for Eikon: (Reporting by Emma Rumney)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-26T14:10:00.000+03:00", "crawled": "2018-04-27T16:23:04.008+03:00", "highlightTitle": ""}